Monoclonal Antibodies Market Size, Share, Growth and Outlook Report
by Susan Hill Business ConsultantThe
global monoclonal antibodies (mAbs) market was valued at
USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion
by 2024. Increasing R&D pertaining to the development of therapeutic mAbs
coupled with supportive government initiatives is expected to drive the
monoclonal antibodies market growth over the forecast period.
Increasing
demand for personalized
medicine is a vital factor responsible for the increasing development
of therapeutic antibodies to provide targeted therapies as every individual
responds in a different manner to a particular treatment. Moreover, related
benefits of using mAbs for therapeutic purposes, including fewer adverse
effects, homogeneity, specificity, and large-scale production, are contributing
toward significant market growth.
In addition,
the government initiatives to enable cost-effective production of mAbs is
anticipated to propel the emergence of this sector over the forecast period.
For instance, the biomanufacturing initiative by National Institute of
Standards and Technology in the U.S. provides scientifically sound regulatory
guidelines to ensure effective and safe manufacturing of protein therapeutics and
to support biopharmaceutical manufacturers in offering low-cost and
high-quality protein drugs across the globe.
Further Key
Findings from the Study Suggest:
- Human-based
mAbs segment is predicted to grow at a lucrative CAGR in the coming years
due to their associated benefits and numerous R&D activities conducted
for further development of human mAbs. Large number of mAbs of human
origin are in phase III clinical trial for cancer treatment
- In vitro
production of mAbs is anticipated to show the fastest growth owing to its
wide-scale adoption by biologics
manufacturers due to its greater efficiency in cost and time
- The research
institute segment is anticipated to exhibit profitable growth due to
increasing R&D efforts in the biotech industry as monoclonal
antibodies have emerged as a major class of therapeutics for several human
diseases, particularly immunological infectious diseases and cancer
- The Asia
pacific region has significant growth potential due to rising government
initiatives in this region supporting the use of mAbs for research and
treatment purposes coupled with the surge in sponsored R&D projects
for the development of cost-effective therapeutic mAbs.
- For instance,
government-led fund providers, such as National Natural Science Foundation
and National Basic Research Program of China, offer financial support
to enterprises and universities to conduct mAb research and development.
- The key players
serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline
plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories,
AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company,
Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services,
Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F.
Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
- The
introduction of advanced methods for mAb production further encourages the
pharmaceutical companies to build their own product pipeline. According to
a study published by NCBI at the end of 2013, approximately 816 companies
were involved in therapeutic protein research.
Grasp advance
knowledge on global monoclonal antibodies (mAbs) industry through in-depth
research insights: www.grandviewresearch.com/research-insights/monoclonal-antibodies-market-insights-adoption-diagnostic-applications-drive-growth
Sponsor Ads
Created on Aug 30th 2019 05:52. Viewed 326 times.